Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

Alborz  Sherafati; Maryam   Mehrpooya; Roya   Sattarzadeh Badkoubeh; Farnoosh   Larti; Farhad   Shahi; Mehrzad  Mirzania; Mohsen  Esfandbod; Mohammad   Saadat; Massoud Ghasemi; Jeyran   Zebardast

doi:10.18502/acta.v57i3.1820

Alborz Sherafati
Maryam Mehrpooya
Roya Sattarzadeh Badkoubeh
Farnoosh Larti
Farhad Shahi
Mehrzad Mirzania
Mohsen Esfandbod
Mohammad Saadat
Massoud Ghasemi
Jeyran Zebardast

DOI: https://doi.org/10.18502/acta.v57i3.1820

Keywords: Breast cancer; Trastuzumab; Carvedilol; Cardiomyopathy

Abstract

Abstract- Breast cancer is the most common cancer among the female population, and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complications. In this study, we aimed to assess the potential benefits of prophylactic carvedilol therapy in patients receiving Herceptin. Sixty five patients with HER2 positive breast cancer were enrolled in the study. All of the patients received Herceptin. Twenty seven patients also received carvedilol 6.25 mg twice daily, and 38 patients had usual care. Echocardiography was performed at baseline, and after three months in both groups and changes in cardiac function, parameters were compared between two groups. After 3 months, LA volume index (P=0.012), TAPSE (P=0.009), Tei index (P=0.015) and Lateral Longitudinal Strain (P=0.024) were significantly better in patients receiving carvedilol. Carvedilol can be effective in the prevention of systolic and diastolic dysfunction following Herceptin therapy.